From the Village Green
Curated from social media posts and threads
🔄 Sector Re-Rating Signals Major M&A Wave
ATB Capital Markets models split Schedule III; analysts flag Verano & Cresco as acquisition targets. Geographic synergy between Trulieve & Curaleaf noted as natural fit.
💚 Curaleaf Completes Four 20 Pharma Buyout
Full acquisition of Germany-licensed producer; operations UK, Poland, Portugal, Canada. Strengthens seed-to-patient supply chain with GMP/GDP compliance.
📋 Trulieve Files DEA Applications
Strategic move ahead of Schedule III relief; 85% of TRUL medical-focused. Analysts model $100M net income swing if 280E tax relief passes.
🎯 Split Schedule III Creates Winners & Losers
Medical-only operators positioned for margin gains; MSOs face tax hurdles. Green Thumb flagged for potential stock doubling within 3 years.
⚖️ Trump’s Partial Rescheduling Creates Confusion
DOJ moved medical cannabis to Schedule III. Only affects prospective FDA-approvals; patients face employment/housing discrimination risk.
🚀 Edibles Market: $55B+ by Mid-2030s
Global edibles $16.6B by 2030; runway to $55B+ driven by wellness. Low-dose THC/CBD for stress, sleep gaining rapid traction worldwide.
🌍 Herbal Dispatch Exports $350K Gummies
First tranche to top-3 global company validates positioning. Active exports across 8+ jurisdictions: Australia, Germany, Portugal, Brazil, Czech Republic, UK, Switzerland, Costa Rica.
💊 Tilray: Rescheduling “Pivotal Moment”
CEO applauds alignment with science for cancer, pain, PTSD, epilepsy patients. Expects accelerated clinical research and broadened access.
🏆 Canopy Apollo: Best Medical Cannabis 2025
Toronto Star Readers Choice reflects patient trust. Premium, patient-first model resonating with Canadian consumers.
📊 Cannabis Market: $125B by 2030
Sector growth fueled by wellness, premium products, functional ingredients. Global expansion opening new distribution channels at scale.
Key Takeaways: Schedule III relief signals material risk improvement for medical operators. M&A wave: Verano, Cresco flagged as targets. TRUL, CURLF, LEAF positioned for margin gains. Edibles: $55B+ by mid-2030s. DEA hearing June 29 pivotal.
Published: Friday, May 1, 2026 | 7:30 AM ET | Curated by Weedstock AI